Present Situation and Prospects on Application of Plant Bioreactor in Pharmaceutical

doi:10.13560/j.cnki.biotech.bull.1985.2015.10.005

Abstract

Abstract: With recent advances on the development and techniques in the life sciences, particularly in genetic engineering and molecular biology, a diverse range of organisms as “factories” can be utilized to produce the products to cure human disease or for preventative measures, i.e., biopharmaceuticals. Currently, bacterial, yeast, invertebrate and mammalian cells as well as plant expression system are already extensively utilized as bioreactors, whilst among them, plant bioreactors have shown the greatest potential, attracting world-wide attentions, due to their easy operation and cost efficiency. In this review, the applications of plant bioreactors, including existing problems and feasible modifying measures are summarized, followed by the prospects on the application and promotion of plant bioreactors based on the biopharmaceutical development trend.

Key words: biopharmaceutical, pharmaceutical proteins, plant bioreactor, protein glycosylation, microRNA

Chen Jinmei, Jiang Luyi, Hong Zhi. Present Situation and Prospects on Application of Plant Bioreactor in Pharmaceutical[J]. Biotechnology Bulletin, 2015, 31(10): 1-7.

References

[1]Walsh G. Biopharmaceutical benchmarks 2010[J]. Nature Biotechnology, 2010, 28（9）：917.
[2]于晓鸿. 中国生物制药产业发展研究[J]. 黑龙江科技信息, 2013（4）：46.
[3]前瞻产业研究. 2013-2017年中国生物制药行业产销需求与投资预测分析报告[R]. 前瞻产业研究院, 2013.
[4] 韩迎. 生物技术药物的优势与前景展望[J]. 中国医院药学杂志, 2013, 33（13）：1083-1085.
[5] 范翠英, 冯利兴, 樊金玲, 等. 重组蛋白表达系统的研究进展[J]. 生物技术, 2012, 22（2）：76-80.
[6] Chen M, Liu X, Wang Z, et al. Modification of plant N-glycans processing：The future of producing therapeutic protein by transgenic plants[J]. Med Res Rev, 2005, 25（3）：343-360.
[7] Sharma AK, Sharma MK. Plants as bioreactors：Recent developments and emerging opportunities[J]. Biotechnology Advances, 2009, 27（6）：811-832.
[8] Ma JKC, Hikmat BY, Wycoff K, et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans[J]. Nature Medicine, 1998, 4（5）：601-606.
[9] http：//www. pharmexec. com/pharmexec/The-First-Plant-Derived-Vaccine-Approved-for-Chick/ArticleStandard/Article/detail/307471.
[10] http：//www. popsci. com/science/article/2012-05/first-plant-derived-biologic-drug-approved-human-use-fda.
[11] He Y, Ning T, Xie T, et al. Large-scale production of functional human serum albumin from transgenic rice seeds[J]. Proc Natl Acad Sci USA, 2011, 108（47）：19078-19083.
[12]Obembe OO, Popoola JO, Leelavathi S, et al. Advances in plant molecular farming[J]. Biotechnol Adv, 2011, 29（2）：210-222.
[13] Pniewski T, Kapusta J, Boci?g P, et al. Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation[J]. J Appl Genet, 2011, 52（2）：125-136.
[14] Bosch D, Schots A. Plant glycans：friend or foe in vaccine development？[J]. Expert Rev Vaccines, 2010, 9（8）：835-842.
[15] Kay R, Chan A, Daly M, et al. Duplication of a CaMV 35S promoter sequences creates a strong enhancer for plant genes[J]. Sciences, 1987, 236：1299-1302.
[16]De Jaeger G, Scheffer S, Jacobs A, et al. Boosting heterologous protein production in transgenic dicotyledonous seeds using Phaseolus vulgaris regulatory sequences[J]. Nature Biotechnology, 2002, 20（12）：1265-1268.
[17]Hennegan K, Yang D, Nguyen D, et al. Improvement of human lysozyme expression in transgenic rice grain by combining wheat（Triticum aestivum）puroindoline b and rice（Oryza sativa）Gt1 promoters and signal peptides[J]. Transgenic Research, 2005, 14（5）：583-592.
[18]Cardi T, Lenzi P, Maliga P. Chloroplasts as expression platforms for plant-produced vaccines[J]. Expert Rev Vaccines, 2010, 9（8）：893-911.
[19]Tregoning JS, Nixon P, Kuroda H, et al. Expression of tetanus toxin fragment C in tobacco chloroplasts[J]. Nucleic Acids Research, 2003, 31（4）：1174-1179.
[20]Davoodi-Semiromi A, Schreiber M, Nalapalli S, et al. Chloroplast‐derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery[J]. Plant Biotechnology Journal, 2010, 8（2）：223-242.
[21] Turpen TH. Tobacco mosaic virus and the virescence of biotechnology[J]. Philos Trans R Soc Lond B Biol Sci, 1999, 354（1383）：665-673.
[22]Kumagai MH, Donson J, della-Cioppa G, et al. Rapid, high-level expression of glycosylated rice α-amylase in transfected plants by an RNA viral vector[J]. Gene, 2000, 245（1）：169-174.
[23]O’Keefe BR, Vojdani F, Buffa V, et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component[J]. Proc Natl Acad Sci USA, 2009, 106（15）：6099-6104.
[24] Bendandi M, Marillonnet S, Kandzia R, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin&s lymphoma[J]. Annals of Oncology, 2010, 21（12）：2420-2427.
[25]Nagels B, Weterings K, Callewaert N, et al. Production of plant made pharmaceuticals：from plant host to functional protein[J]. Critical Reviews in Plant Sciences, 2012, 31（2）：148-180.
[26]Gomord V, Fitchette AC, Menu-Bouaouiche L, et al. Plant-specific glycosylation patterns in the context of therapeutic protein production[J]. Plant Biotechnol J, 2010, 8（5）：564-587.
[27] van Ree R, Cabanes-Macheteau M, Akkerdaas J, et al. β（1, 2）-xylose and α（1, 3）-fucose residues have a strong contribution in IgE binding to plant glycoallergens[J]. J Biol Chem, 2000, 275（15）：11451-11458.
[28] Jin C, Altmann F, Strasser R, et al. A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits[J]. Glycobiology, 2008, 18（3）：235-241.
[29] Cox KM, Sterling JD, Regan JT, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor[J]. Nature Biotechnology, 2006, 24（12）：1591-1597.
[30] Sourrouille C, Marquet-Blouin E, D&Aoust MA, et al. Down‐regulated expression of plant-specific glycoepitopes in alfalfa[J]. Plant Biotechnology Journal, 2008, 6（7）：702-721.
[31]Strasser R, Stadlmann J, Sch?hs M, et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure[J]. Plant Biotechnol J, 2008, 6（4）：392-402.
[32]Castilho A, Strasser R, Stadlmann J, et al. In planta protein sialylation through overexpression of the respective mammalian pathway[J]. J Biol Chem, 2010, 285（21）：15923-15930.
[33]Zhang L, Hou D, Chen X, et al. Exogenous plant MIR168a specifi-cally targets mammalian LDLRAP1：evidence of cross-kingdom regulation by microRNA[J]. Cell Research, 2011, 22（1）：107-126.